"The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) for patients with Waldenström’s macroglobulinemia (WM), a rare form of cancer that begins in the body’s immune system. The drug receiv"...
Pamidronate Disodium Injection
Pamidronate Disodium Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Pamidronate Disodium Injection is a bone resorption inhibitor used to treat moderate or severe hypercalcemia associated with malignancy (cancer), with or without bone metastases. Pamidronate disodium injection is also used to treat moderate to severe Paget's disease of bone, and osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma. Pamidronate disodium injection is available in generic form. Common side effects of pamidronate disodium injection include:
- catheter site reactions (swelling, redness, or pain)
- abdominal pain
- loss of appetite
- inflammation of the mouth and lips
- runny nose
- upper respiratory tract infection
- drowsiness, and
- muscle pain
The dose of pamidronate disodium depends on the condition being treated. Pamidronate disodium may interact with other potentially nephrotoxic drugs, and thalidomide. Tell your doctor all medications and supplements you use. Pamidronate disodium is not recommended for use during pregnancy. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.
Our Pamidronate Disodium Injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Pamidronate Disodium FDA Prescribing Information: Side Effects
Hypercalcemia of Malignancy
Transient mild elevation of temperature by at least 1°C was noted 24 to 48 hours after administration of pamidronate disodium in 34% of patients in clinical trials. In the saline trial, 18% of patients had a temperature elevation of at least 1°C 24 to 48 hours after treatment.
Drug-related local soft-tissue symptoms (redness, swelling or induration and pain on palpation) at the site of catheter insertion were most common in patients treated with 90 mg of pamidronate disodium. Symptomatic treatment resulted in rapid resolution in all patients.
Five of 231 patients (2%) who received pamidronate disodium during the four U.S. controlled hypercalcemia clinical studies were reported to have had seizures, 2 of whom had preexisting seizure disorders. None of the seizures were considered to be drug-related by the investigators. However, a possible relationship between the drug and the occurrence of seizures cannot be ruled out. It should be noted that in the saline arm 1 patient (4%) had a seizure.
There are no controlled clinical trials comparing the efficacy and safety of 90 mg pamidronate disodium over 24 hours to 2 hours in patients with hypercalcemia of malignancy. However, a comparison of data from separate clinical trials suggests that the overall safety profile in patients who received 90 mg pamidronate disodium over 24 hours is similar to those who received 90 mg pamidronate disodium over 2 hours. The only notable differences observed were an increase in the proportion of patients in the pamidronate disodium 24 hour group who experienced fluid overload and electrolyte/mineral abnormalities.
At least 15% of patients treated with pamidronate disodium for hypercalcemia of malignancy also experienced the following adverse events during a clinical trial:
General: Fluid overload, generalized pain
Genitourinary: Urinary tract infection
Musculoskeletal: Bone pain
Many of these adverse experiences may have been related to the underlying disease state.
The following table lists the adverse experiences considered to be treatment-related during comparative, controlled U.S. trials.
Treatment-Related Adverse Experiences Reported in Three U.S.
Controlled Clinical Trials
|Percent of Patients|
over 4 hr
over 24 hr
over 24 hr
|Upper respiratory infection||0||3||0||0||0|
|Hemic and Lymphatic|
|Abnormal liver function||0||0||0||3||0|
Transient mild elevation of temperature > 1°C above pretreatment baseline was noted within 48 hours after completion of treatment in 21% of the patients treatedwith 90 mg of pamidronate disodium in clinical trials.
Drug-related musculoskeletal pain and nervous system symptoms (dizziness, headache, paresthesia, increased sweating) were more common in patients with Paget's disease treated with 90 mg of pamidronate disodium than in patients with hypercalcemia of malignancy treated with the same dose.
Adverse experiences considered to be related to trial drug, which occurred in at least 5% of patients with Paget's disease treated with 90 mg of pamidronate disodium in two U.S. clinical trials, were fever, nausea, back pain, and bone pain.
At least 10% of all pamidronate disodium-treated patients with Paget's disease also experienced the following adverse experiences during clinical trials:
Musculoskeletal: Arthrosis, bone pain
Nervous system: Headache
Most of these adverse experiences may have been related to the underlying disease state.
Osteolytic Bone Metastases of Breast Cancer and Osteolytic Lesions of Multiple Myeloma
The most commonly reported ( > 15%) adverse experiences occurred with similar frequencies in the pamidronate disodium and placebo treatment groups, and most of these adverse experiences may have been related to the underlying disease state or cancer therapy.
Commonly Reported Adverse Experiences in Three U.S. Controlled
Disodium 90 mg
over 4 hours
Disodium 90 mg
over 2 hours
|Hemic and Lymphatic|
|Upper Respiratory Tract Infection||32.2||28.3||19.6||20.2||24.1||22.9|
|Urinary Tract Infection||15.6||9.1||20.2||17.6||18.5||15.6|
Of the toxicities commonly associated with chemotherapy, the frequency of vomiting, anorexia, and anemia were slightly more common in the pamidronate disodium patients whereas stomatitis and alopecia occurred at a frequency similar to that in placebo patients. In the breast cancer trials, mild elevations of serum creatinine occurred in 18.5% of pamidronate disodium patients and 12.3% of placebo patients. Mineral and electrolyte disturbances, including hypocalcemia, were reported rarely and in similar percentages of pamidronate disodium-treated patients compared with those in the placebo group. The reported frequencies of hypocalcemia, hypokalemia, hypophophatemia, and hypomagnesemia for pamidronate disodium-treated patients were 3.3%, 10.5%, 1.7%, and 4.4%, respectively, and for placebo-treated patients were 1.2%, 12%, 1.7%, and 4.5%, respectively. In previous hypercalcemia of malignancy trials, patients treated with pamidronate disodium (60 or 90 mg over 24 hours) developed electrolyte abnormalities more frequently (see ADVERSE REACTIONS, Hypercalcemia of Malignancy).
Arthralgias and myalgias were reported slightly more frequently in the pamidronate disodium group than in the placebo group (13.6% and 26% vs 10.8% and 20.1%, respectively).
In multiple myeloma patients, there were five pamidronate disodium-related serious and unexpected adverse experiences. Four of these were reported during the 12 month extension of the multiple myeloma trial. Three of the reports were of worsening renal function developing in patients with progressive multiple myeloma or multiple myeloma-associated amyloidosis. The fourth report was the adult respiratory distress syndrome developing in a patient recovering from pneumonia and acute gangrenous cholecystitis. One pamidronate disodium-treated patient experienced an allergic reaction characterized by swollen and itchy eyes, runny nose, and scratchy throat within 24 hours after the sixth infusion.
In the breast cancer trials, there were four pamidronate disodium-related adverse experiences, all moderate in severity, that caused a patient to discontinue participation in the trial. One was due to interstitial pneumonitis, another to malaise and dyspnea. One pamidronate disodium patient discontinued the trial due to a symptomatic hypocalcemia. Another pamidronate disodium patient discontinued therapy due to severe bone pain after each infusion, which the investigator felt was trial-drug-related.
In a study of the safety and efficacy of pamidronate disodium 90 mg (2 hour infusion) versus Zometa 4 mg (15 minute infusion) in bone metastases patients with multiple myeloma or breast cancer, renal deterioration was defined as an increase in serum creatinine of 0.5 mg/dL for patients with normal baseline creatinine ( < 1.4 mg/dL) or an increase of 1.0 mg/dL for patients with an abnormal baseline creatinine ( ≥ 1.4 mg/dL). The following are data on the incidence of renal deterioration in patients in this trial. See Table below.
Incidence of Renal Function Deterioration in Multiple Myeloma
and Breast Cancer Patients with Normal and Abnormal Serum Creatinine at Baseline*
|Patient Population/Baseline Creatinine||Pamidronate Disodium 90 mg/2 hours||Zometa® 4 mg/15 minutes|
|*Patients were randomized following the 15-minute infusion amendment for the Zometa arm.|
The following adverse reactions have been reported in post-marketing use: General: reactivation of Herpes simplex and Herpes zoster, influenza-like symptoms;CNS: confusion and visual hallucinations, sometimes in the presence of electrolyte imbalance; Skin: rash, pruritus; Special senses: conjunctivitis; Renal: focal segmental glomerulosclerosis including the collapsing variant, nephrotic syndrome; Laboratory abnormalities: hyperkalemia, hypernatremia, hematuria. Rare instances of allergic manifestations have been reported, including hypotension, dyspnea, or angioedema, and very rarely, anaphylactic shock. Pamidronate disodium is contraindicated in patients with clinically significant hypersensitivity to pamidronate disodium or other bisphosphonates (see CONTRAINDICATIONS).
Cases of osteonecrosis (primarly of the jaws) have been reported since market introduction. Osteonecrosis of the jaws has other well documented multiple risk factors. It is not possible to determine if these events are related to pamidronate disodium or other bisphosphonates, to concomitant drugs or other therapies (e.g., chemotherapy, radiotherapy, corticosteroid), to patient's underlying disease, or to other comorbid risk factors (e.g., anemia, infection, preexisting oral disease). (See PRECAUTIONS.)
Read the entire FDA prescribing information for Pamidronate Disodium (Pamidronate Disodium Injection)
Additional Pamidronate Disodium Injection Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.